JP2019510079A5 - - Google Patents

Download PDF

Info

Publication number
JP2019510079A5
JP2019510079A5 JP2018563946A JP2018563946A JP2019510079A5 JP 2019510079 A5 JP2019510079 A5 JP 2019510079A5 JP 2018563946 A JP2018563946 A JP 2018563946A JP 2018563946 A JP2018563946 A JP 2018563946A JP 2019510079 A5 JP2019510079 A5 JP 2019510079A5
Authority
JP
Japan
Prior art keywords
compound
use according
disease
disorder
vasoconstriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510079A (ja
Filing date
Publication date
Priority claimed from GBGB1603311.0A external-priority patent/GB201603311D0/en
Application filed filed Critical
Publication of JP2019510079A publication Critical patent/JP2019510079A/ja
Publication of JP2019510079A5 publication Critical patent/JP2019510079A5/ja
Pending legal-status Critical Current

Links

JP2018563946A 2016-02-25 2017-02-24 血管収縮を特徴とする疾患を治療する方法 Pending JP2019510079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603311.0A GB201603311D0 (en) 2016-02-25 2016-02-25 New uses and methods
GB1603311.0 2016-02-25
PCT/GB2017/050498 WO2017144909A1 (en) 2016-02-25 2017-02-24 Methods of treating diseases characterised by vasoconstriction

Publications (2)

Publication Number Publication Date
JP2019510079A JP2019510079A (ja) 2019-04-11
JP2019510079A5 true JP2019510079A5 (enExample) 2020-04-02

Family

ID=55806947

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018563946A Pending JP2019510079A (ja) 2016-02-25 2017-02-24 血管収縮を特徴とする疾患を治療する方法

Country Status (9)

Country Link
US (2) US20190038603A1 (enExample)
EP (1) EP3419620A1 (enExample)
JP (1) JP2019510079A (enExample)
CN (1) CN109069487A (enExample)
AU (1) AU2017222406B2 (enExample)
CA (1) CA3014728A1 (enExample)
GB (1) GB201603311D0 (enExample)
RU (1) RU2018133818A (enExample)
WO (1) WO2017144909A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102697255B1 (ko) 2017-10-19 2024-08-23 데이진 화-마 가부시키가이샤 벤즈이미다졸 유도체 및 이의 용도
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
EP3876930A4 (en) 2018-11-07 2022-07-20 Dana-Farber Cancer Institute, Inc. BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND THEIR USES
KR20210059663A (ko) * 2019-11-15 2021-05-25 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4267574B1 (en) 2020-12-23 2025-04-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
JP7782035B2 (ja) 2021-11-09 2025-12-08 エイジャックス セラピューティクス, インコーポレイテッド Jak2阻害剤としての6-ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
WO2023086320A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of jak2
TW202345806A (zh) 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔5,4-b〕吡啶malt-1抑制劑
US20250340557A1 (en) * 2022-07-06 2025-11-06 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
GB202212749D0 (en) 2022-09-01 2022-10-19 Gesynta Pharma Ab New uses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100298343A1 (en) * 2007-10-05 2010-11-25 John Howard Hutchinson 5-lipoxygenase-activating protein (flap) inhibitors
UY32470A (es) * 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2011023812A1 (en) * 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
US8759537B2 (en) * 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
EP2495244A1 (en) * 2011-03-02 2012-09-05 NovaSaid AB Piperidinyl benzoimidazole derivatives as mPGEs-1 inhibitors
PL2746265T3 (pl) * 2011-08-18 2016-04-29 Nippon Shinyaku Co Ltd POCHODNA HETEROCYKLICZNA JAKO INHIBITOR MIKROSOMALNEJ SYNTAZY PROSTAGLANDYNY E (mPGEs)
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
ES2838625T3 (es) * 2014-04-14 2021-07-02 Shanghai hengrui pharmaceutical co ltd Derivados de amida y sales farmacéuticamente aceptables de los mismos, su método de preparación y aplicación médica de los mismos

Similar Documents

Publication Publication Date Title
JP2019510079A5 (enExample)
RU2018133818A (ru) Способы лечения заболеваний, характеризующихся вазоконстрикцией
JP2021509912A5 (enExample)
JP2014511891A5 (enExample)
JP2015504081A5 (enExample)
JP2017149726A5 (enExample)
JP2018193377A5 (enExample)
JP2016147915A5 (enExample)
JP2014511892A5 (enExample)
JP2017178948A5 (enExample)
JP2016106149A5 (enExample)
JP2017527532A5 (enExample)
JP2017504611A5 (enExample)
JP2019529541A5 (enExample)
JP2013519675A5 (enExample)
JP2014530874A5 (enExample)
JP2015083580A5 (enExample)
JP2019516739A5 (enExample)
CN111836807A (zh) 氧杂螺环类化合物及其制备方法和用途
JP2016510326A5 (enExample)
JP2015516427A5 (enExample)
JP2017533930A5 (enExample)
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2016505637A5 (enExample)
JP2012517449A5 (enExample)